fashion -WSS

fashion

author：comprehensive 2025-10-01 22:59:24 - browse：427

The Food and Drug Administration on Friday approved a new, rapid-acting medicine made by Sage Therapeutics to treat postpartum depression, the first oral treatment for the condition. But the agency denied the company’s application for an indication for major depression, a much larger potential market.

The drug, which will be sold under the brand name Zurzuvae, is not meant to be taken chronically. Patients take it orally for 14 days. In two clinical trials, the drug was found to significantly improve depressive symptoms more than a placebo. The effect was maintained for four weeks after treatment.

“Maternal mental health has been sidelined for far too long, but today’s approval of Zurzuvae helps to change that. Women have been waiting for an oral medicine that can specifically and rapidly improve the symptoms of PPD and we are proud to be able to deliver that,” said Barry Greene, Sage’s CEO, in a press release.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： The thinking behind the controversial eating disorder chatbot Tessa

WSS

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

Crowdfunding for unproven stem cell procedures spreads misinformation

Skip the lead apron during X

Hubble vs. James Webb telescope images: See the difference

Mom launches Girl Scout troop for LGBTQ youth in Texas

Living organ donors deserve priority status for transplants

focus

fashion

knowledge

23andMe had bad news about my health. I wish a person had delivered it

Beware reading your test results before your doctor does

Jerome Adams on the need for new antivirals for Covid

Skip the lead apron during X

Novavax promises a turnaround & Lilly roils the obesity market

Use doctors trained outside the U.S. to ease the physician shortage

United colonoscopy coverage change 'may cost lives,' doctors say

Biden administration plans revamp of organ transplant system

Virginia high school admissions case could be legal follow

Eli Lilly’s Mounjaro succeeds in second weight

focus

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

AstraZeneca lung cancer study comes in below expectations

'Screen and refer' systems are hurting patients

Bispecific antibodies are next new thing in cancer immunotherapy

FDA approves first new drug developed for postpartum depression

Being 'nonadherent' patient made me a more empathetic doctor

leisure time

hotspot

entertainment

leisure time